HC278 is a selective TEAD1/TEAD3 PROTAC degrader. HC278 induces proteasome-dependent degradation by forming a stable ternary complex with CRBN/DDB1. HC278 is applicable to the research of mesothelioma.

GNE-140 is an orally active and selective inhibitor of lactate dehydrogenase (LDH) A, B and C, with IC50 values of 3, 5 and 5 nM against LDHA, LDHB, LDHC, respectively. GNE-140 blocks the conversion of pyruvate to lactate, reduces lactate production and histone lysine lactylation, and inhibits glycolysis. GNE-140 attenuates cardiac hypertrophy, alleviates PM2.5-induced pulmonary inflammation and fibrosis, blocks MRSA-induced Arg1 expression, regulates metabolites of glycolysis and the pentose phosphate pathway, reduces glucose uptake, increases ROS, and induces cancer cell apoptosis. GNE-140 is applicable to research related to pathological cardiac hypertrophy, pulmonary fibrosis, MRSA infection and pancreatic cancer.

Ganglioside GQ1b (porcine brain) (tetraammonium) is a glycosphingolipid.

Fumarranol, a Fumagillin analogue, is a selective type 2 methionine aminopeptidase (MetAP2) inhibitor with a human IC50 of 3.2 μM. Fumarranol inhibits proliferation of bovine aortic endothelial cells and inhibits angiogenesis in a mouse matrigel plug model. Fumarranol can be used for the researches of cancer, diabetic retinopathy, age-related macular degeneration.

Flubeneteram is a succinate dehydrogenase inhibitor with an IC50 of 0.0484 μM. Flubeneteram disrupts succinate dehydrogenase activity. Flubeneteram demonstrates protective effects against Rhizoctonia solani and Sphaerotheca fuliginea in preclinical models. Flubeneteram can be used for research related to fungal infections.

FLT3-IN-39 (Compound W4) is a selective FLT3 inhibitor, with an IC50 value of 16.0 nM against FLT3-ITD and an IC50 value of 20.4 nM against FLT3-D835Y. FLT3-IN-39 inhibits FLT3-ITD and FLT3-D835Y mutant kinases. FLT3-IN-39 induces G0/G1 cell cycle arrest and Apoptosis in cancer cells, and reduces intracellular ROS levels. FLT3-IN-39 exhibits anti-tumor activity against acute myeloid leukemia.

FGFR-IN-26 is an orally active FGFR inhibitor. FGFR-IN-26 inhibits FGFR2 wild-type and clinically relevant resistance mutations. FGFR-IN-26 inhibits tumor growth in FGFR2-amplified xenograft mouse models. FGFR-IN-26 can be used for the research of cancer, suah as gastric carcinoma.

Fenaminstrobin (SYP-1620) is a strobilurin Fungicide. Fenaminstrobin binds to cytochrome bc1 in the mitochondrial respiratory chain, thereby inhibiting ATP production. Fenaminstrobin exhibits acute toxicity to Daphnia magna. Fenaminstrobin effectively controls diseases such as Fusarium ear rot, downy mildew, rice blast and pear scab.

Etimicin is a fourth-generation semisynthetic aminoglycoside antibiotic. Etimicin exhibits broad spectrum of activity against gram-positive, gram-negative, and aminoglycoside-resistant bacterial strains, with lower ototoxicity and nephrotoxicity. Etimicin exerts rapid, concentration-dependent bactericidal activity against bacteria. Etimicin can be used for the research of bacterial infections.

EDP-420 (EP-013420; S-013420) is an orally active antibacterial agent. EDP-420 inhibits the Mycobacterium avium complex (MAC) in macrophages. EDP-420 reduces bacterial counts in a mouse model of macrolide infection. EDP-420 inhibits pneumococcal activity in a rabbit model of meningitis. EDP-420 can be used in research on inflammatory infectious diseases such as meningitis.

EC0652 is a PSMA imaging agent with SPECT imaging capability. EC0652 can be used for the research of metastatic castration-resistant prostate cancer.

DNA-PK-IN-16 is an orally active DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 of 10.2 nM. DNA-PK-IN-16 induces the upregulation of γH2A.X, a biomarker of DNA double-strand breaks. DNA-PK-IN-16 exhibits antiproliferative activity in various cancer cell lines. DNA-PK-IN-16 enhances the infiltration of CD8+ T cells in tumor tissues through synergistic action with anti-PD-L1 monoclonal antibody. DNA-PK-IN-16 is applicable for cancer research.

CXCR6 antagonist 1 (Compound 81) is an orally active CXCR6 antagonist. CXCR6 antagonist 1 inhibits the CXCR6 receptor signaling pathway, including β-arrestin recruitment and Forskolin-induced cAMP production. CXCR6 antagonist 1 reduces tumor growth in a mouse xenograft model of hepatocellular carcinoma. CXCR6 antagonist 1 can be used in research related to hepatocellular carcinoma.

CSN5-IN-3 (Compound 30) is a CSN5 inhibitor with an IC50 of 0.58 μM. CSN5-IN-3 inhibits the enzymatic activity of CSN5, leading to increased accumulation of NEDD8-Cul1 and promoting the degradation of PD-L1. CSN5-IN-3 downregulates Bcl-2, and upregulates P53 and Cleaved caspase-3. CSN5-IN-3 exhibits anticancer activity against triple-negative breast cancer.

CRBN ligand-895 (Compound 14) is an E3 ubiquitin ligase ligand for cereblon (CRBN), which is used to recruit the cereblon protein. CRBN ligand-895 can be used for the synthesis of PROTACs, such as PROTAC HDAC8 Degrader-4.

ClpP activator-2 (Compound GU18) is a ClpP activator with a Kd of 5.01 μM for HsClpP. ClpP activator-2 enhances the proteolytic activity of HsClpP and promotes the degradation of α-casein by HsClpP, with an EC50 of 1.09 μM. ClpP activator-2 induces the accumulation of mitochondrial reactive oxygen species (ROS), leading to damage to mitochondrial structure and function. ClpP activator-2 exhibits significant in vivo anti-multiple myeloma activity.

cis-3-(Aminomethyl)cyclobutanol hydrochloride is a PROTAC linker that can be used in the synthesis of PROTACs.

CDK8-IN-2 is an orally active CDK8 inhibitor of an IC50 values of 0.010 μM. CDK8-IN-2 shows a CDK19 IC50 value of 0.026 μM. CDK8-IN-2 inhibits phospho-STAT1, a pharmacodynamic biomarker of CDK8. CDK8-IN-2 inhibits WNT pathway activity. CDK8-IN-2 can be used for the research of colorectal carcinoma.

CB1-receptor agonist-1 is the racemic form of compound ‘1350 and is also a cannabinoid-1 receptor (CB1R) agonist.

Cathepsin C-IN-7 (Page 68) is a Cathepsin C inhibitor. Cathepsin C-IN-7 can be used in research related to primary cancers and cancer metastases.

C20-Dihydrosphingomyelin (C20-DHSM; DHSM (d18:0/20:0)) is a saturated form of Sphingomyelin. C20-Dihydrosphingomyelin is a secondary component of most cell sphingolipids and its levels significantly decrease after intermittent fasting during Ramadan. C20-Dihydrosphingomyelin can be used for the development of liposome reagents.

C11-BODIPY 505/515 Glucosyl ceramide is a C11-BODIPY 505/515-labeled Glucosyl ceramide that can be used to prepare lipid nanoparticles for drug delivery (Ex/Em = 505/515 nm).

Br-C1-CONH-C5-CO-Val-Cit-PAB-MMAE (compound 62) is a drug-linker conjugate that contains a monomethyl auristatin E (MMAE) drug moiety, which is linked to a bromoacetamide-containing extension unit via a valine-citrulline (Val-Cit) dipeptide and a self-immolative p-aminobenzyl (PAB) spacer. Br-C1-CONH-C5-CO-Val-Cit-PAB-MMAE is applicable to the research of breast cancer, anaplastic large cell lymphoma and lung adenocarcinoma.

BR103354 is an orally active, selective fibroblast activation protein (FAP) inhibitor with an IC50 value of 14 nM against hFAP. BR103354 restores the levels of phosphorylated ERK and Glut1 that are reduced by co-treatment with hFGF21 and FAP, decreases non-fasting blood glucose concentrations, improves glucose tolerance, and reduces hepatic triglyceride content. BR103354 ameliorates hepatic steatosis and hepatic fibrosis. BR103354 can be used in the research of type 2 diabetes and non-alcoholic steatohepatitis.

BODIPY TMR Lyso PA ester ammonium is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.

AP-7-168, molecular glues, is a β-arrestin-biased negative allosteric modulator of the β2-adrenergic receptor (β2AR). AP-7-168 can promote β2AR homodimerization and inhibit GRK5-mediated β2AR phosphorylation. AP-7-168 can sustain bronchorelaxation in cell and tissue. AP-7-168 can be used for the researches of inflammation and immunology, such as asthma.

Antitumor agent-214 is a chalcone analogue with anti-tumor activity. Antitumor agent-214 induces cell cycle arrest and apoptosis in tumor cells, disrupts mitochondrial metabolism, and upregulates the expression of caspase 3, caspase 7 and caspase 9, downregulates PARP1. Antitumor agent-214 can be used for anti-tumor research related to colorectal cancer, breast cancer, lung cancer, and cervical cancer.

Antioxidant 245 (AO-245) is a hindered phenol antioxidant. Antioxidant 245 can be used in the research of nanocomposites.

Amonafide L-malate is a topoisomerase II inhibitor and DNA intercalator that induces Apoptotic signaling by blocking the binding of Topo II to DNA.

AK177 is an allosteric activator of IRE1α ribonuclease, with values of 480 nM and 180 nM against non-phosphorylated and phosphorylated IRE1α, respectively.\n